AstraZeneca agrees to $520M settlement in Seroquel cases
AstraZeneca agreed to pay $520 million to end two federal investigations and two whistle-blower lawsuits related to an alleged improper sale and promotion of antipsychotic Seroquel. A spokesman for AstraZeneca said the company is in final talks with the Justice Department for a corporate-integrity agreement and declined to give further details of the settlement.
New York Times, The | 10/29
This story published in FDLI SmartBrief on 10/30/2009
More from SmartBrief:
Pfizer fined $2.3 billion for illegal marketing of 13 drugs
Thursday, September 3, 2009
Pfizer unit is fined $1.3B for off-label marketing of 4 drugs
Monday, October 26, 2009
IVAX, Omnicare settle kickback allegations regarding Risperdal
Monday, November 9, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|